Parke-Davis is currently out of stock of Ketalar (ketamine hydrochloride) 100mg/ml injection, 10ml. The company says that this has been brought about by both a batch failure and a worldwide shortage of ketamine and that the situation is likely to continue until the end of March. Other presentations of Ketalar are unaffected.